Notably, the post-GVAX tumor infiltration and aggregate formation also triggered counter-regulatory mechanisms, including increased PD-1/PD-L1 signaling, implying that vaccine-primed PDAC might be more responsive to subsequent immune-checkpoint therapies than vaccine-naïve tumors. The gene discussed is CD274; the disease is neoplasm.